Do recipients of kidneys from donors treated with streptokinase develop anti-streptokinase antibodies?

Transplant Proc. 2005 Oct;37(8):3272-3. doi: 10.1016/j.transproceed.2005.09.035.

Abstract

Streptokinase is used for preflush for non-heart-beating donors (NHBDs) in our center. The aim of this study was to evaluate whether the use of thrombolytic streptokinase results in the production of anti-streptokinase antibodies in the recipients after renal transplantation. Recipient sera taken prior to and at 1 and 6 months posttransplant were tested for the presence of antibodies to streptokinase using an enzyme-linked immunosorbent assay assay. No differences were detected between a group of 18 recipients who had kidneys from thrombolytic-treated NHBDs and a further group of 18 who received NHBD kidneys without such treatment.

Publication types

  • Comparative Study

MeSH terms

  • Antibodies / blood*
  • Antibody Formation
  • Fibrinolytic Agents / therapeutic use*
  • Heart Arrest
  • Humans
  • Kidney Transplantation / immunology*
  • Retrospective Studies
  • Streptokinase / immunology*
  • Streptokinase / therapeutic use*
  • Tissue Donors

Substances

  • Antibodies
  • Fibrinolytic Agents
  • Streptokinase